摘要
目的:探讨MGMT蛋白在乳腺癌中的表达及其与乳腺癌预后的关系。方法:应用免疫组化法检测135例乳腺癌患者MGMT蛋白的表达,并探讨其与乳腺癌临床特征及预后的关系。结果:135例乳腺癌中MGMT蛋白总阳性率为84.4 %(114/135),但存在异质性。MGMT蛋白的阳性表达与患者年龄、月经状态、原发肿瘤大小、淋巴结转移情况及肿瘤的临床分期无明显相关性(P>0.05),与生存期无明显相关性(P>0.05),但与ER状况相关(P<0.025)。结论:MGMT蛋白的表达不能作为乳腺癌的一个预后指标。
Objective: To analyze the relationship between MGMT protein and its prognostic significance in breast carcinoma. Methods: The expression of MGMT protein in 135 cases of breast carcinoma was detected by immunohistochemical method,and exploring the possible functions of MGMT in breast carcinoma development and progression. Results: The expression rates of MGMT protein was 84.4 %(114/135), while 21 patients had no detectable or low level of MGMT expression(15.6 %). The expression of MGMT protein had no relationship with age, menses stage, tumor size, lymph node metastasis, clinical stage and survival time of breast carcinoma(P>0.05),but had close relationship with the ERα expression(P<0.025). Conclusion: The expression of MGMT protein can not be a prognostic factor of breast carcinoma.
出处
《肿瘤研究与临床》
CAS
2004年第2期88-90,共3页
Cancer Research and Clinic
